• This record comes from PubMed

Molecular markers in well-differentiated thyroid cancer

. 2018 Jun ; 275 (6) : 1375-1384. [epub] 20180406

Language English Country Germany Media print-electronic

Document type Journal Article, Review

Links

PubMed 29626249
DOI 10.1007/s00405-018-4944-1
PII: 10.1007/s00405-018-4944-1
Knihovny.cz E-resources

PURPOSE: Thyroid nodules are of common occurrence in the general population. About a fourth of these nodules are indeterminate on aspiration cytology placing many a patient at risk of unwanted surgery. The purpose of this review is to discuss various molecular markers described to date and place their role in proper perspective. This review covers the fundamental role of the signaling pathways and genetic changes involved in thyroid carcinogenesis. The current literature on the prognostic significance of these markers is also described. METHODS: PubMed was used to search relevant articles. The key terms "thyroid nodules", "thyroid cancer papillary", "carcinoma papillary follicular", "carcinoma papillary", "adenocarcinoma follicular" were searched in MeSH, and "molecular markers", "molecular testing", mutation, BRAF, RAS, RET/PTC, PAX 8, miRNA, NIFTP in title and abstract fields. Multiple combinations were done and a group of experts in the subject from the International Head and Neck Scientific Group extracted the relevant articles and formulated the review. RESULTS: There has been considerable progress in the understanding of thyroid carcinogenesis and the emergence of numerous molecular markers in the recent years with potential to be used in the diagnostic algorithm of these nodules. However, their precise role in routine clinical practice continues to be a contentious issue. Majority of the studies in this context are retrospective and impact of these mutations is not independent of other prognostic factors making the interpretation difficult. CONCLUSION: The prevalence of these mutations in thyroid nodule is high and it is a continuously evolving field. Clinicians should stay informed as recommendation on the use of these markers is expected to evolve.

See more in PubMed

Hum Pathol. 2016 Aug;54:134-42 PubMed

Cancer. 2012 Apr 1;118(7):1764-73 PubMed

Cancer. 2014 Dec 1;120(23 ):3627-34 PubMed

Arch Pathol Lab Med. 2011 May;135(5):569-77 PubMed

Am J Clin Pathol. 2003 Jul;120(1):71-7 PubMed

Cell. 2014 Oct 23;159(3):676-90 PubMed

Ann Surg Oncol. 2013 Jan;20(1):47-52 PubMed

Endocr Pathol. 2002 Spring;13(1):3-16 PubMed

Thyroid. 2009 Dec;19(12 ):1351-61 PubMed

Thyroid. 2016 Jul;26(7):911-5 PubMed

J Clin Endocrinol Metab. 2006 Sep;91(9):3603-10 PubMed

Ann Surg Oncol. 2009 Feb;16(2):240-5 PubMed

Cancer. 2007 Jul 1;110(1):38-46 PubMed

Histopathology. 2018 Jan;72 (1):6-31 PubMed

Thyroid. 2000 Jan;10(1):19-23 PubMed

Otolaryngol Clin North Am. 2014 Aug;47(4):557-71 PubMed

Endocr Relat Cancer. 2015 Apr;22(2):159-68 PubMed

Int J Clin Exp Med. 2013;6(1):74-80 PubMed

N Engl J Med. 2016 Aug 18;375(7):614-7 PubMed

N Engl J Med. 2012 Aug 23;367(8):705-15 PubMed

J Clin Oncol. 2015 Jan 1;33(1):42-50 PubMed

Cancer Cytopathol. 2017 May;125(5):323-331 PubMed

J Clin Endocrinol Metab. 2000 Mar;85(3):1170-5 PubMed

Otolaryngol Clin North Am. 2014 Aug;47(4):573-93 PubMed

Clin Endocrinol (Oxf). 1999 Apr;50(4):529-35 PubMed

J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6 PubMed

Nat Rev Cancer. 2013 Mar;13(3):184-99 PubMed

Clin Cancer Res. 2000 Mar;6(3):1093-103 PubMed

Am J Surg Pathol. 2006 Feb;30(2):216-22 PubMed

J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90 PubMed

JAMA Oncol. 2016 Aug 1;2(8):1023-9 PubMed

Curr Opin Otolaryngol Head Neck Surg. 2013 Apr;21(2):135-42 PubMed

Ann Surg Oncol. 2010 Dec;17(12):3294-300 PubMed

J Clin Endocrinol Metab. 2001 May;86(5):2187-90 PubMed

Cancer. 2009 Jun 25;117(3):195-202 PubMed

J Clin Endocrinol Metab. 2015 Jul;100(7):2743-50 PubMed

Cancer Med. 2015 Jun;4(6):791-9 PubMed

Thyroid. 2016 Jan;26(1):1-133 PubMed

Endocr Connect. 2017 Apr;6(3):R8-R17 PubMed

Am J Clin Pathol. 2009 Nov;132(5):658-65 PubMed

Science. 2000 Aug 25;289(5483):1357-60 PubMed

Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1 PubMed

J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 PubMed

J Clin Endocrinol Metab. 1997 Apr;82(4):1306-7 PubMed

Hum Pathol. 2014 Jul;45(7):1339-47 PubMed

Endocr Pract. 2014 Apr;20(4):360-3 PubMed

J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60 PubMed

J Clin Invest. 2016 Mar 1;126(3):1052-66 PubMed

Endocrinol Metab (Seoul). 2015 Sep;30(3):252-62 PubMed

J Clin Oncol. 2003 Sep 1;21(17):3226-35 PubMed

J Clin Pathol. 2017 Jun;70(6):500-507 PubMed

J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 PubMed

J Clin Endocrinol Metab. 2012 Jun;97(6):1905-12 PubMed

Thyroid. 2011 Mar;21(3):243-51 PubMed

Cancer Cytopathol. 2016 Oct;124(10 ):711-721 PubMed

J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9 PubMed

Endocr Relat Cancer. 2006 Jun;13(2):497-508 PubMed

Arch Pathol Lab Med. 2016 Dec;140(12 ):1338-1344 PubMed

J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8 PubMed

J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 PubMed

Thyroid. 2015 Jul;25(7):716-59 PubMed

Thyroid. 2017 Nov;27(11):1341-1346 PubMed

J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 PubMed

Endocr Pract. 2017 Aug;23 (8):979-988 PubMed

J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 PubMed

Thyroid. 2017 Apr;27(4):506-511 PubMed

Arch Intern Med. 1994 Aug 22;154(16):1838-40 PubMed

JAMA. 2013 Apr 10;309(14):1493-501 PubMed

Cancer. 2018 Apr 15;124(8):1682-1690 PubMed

Endocr Relat Cancer. 2013 Jul 12;20(4):603-10 PubMed

Head Neck. 2013 Oct;35(10):1499-506 PubMed

Medicine (Baltimore). 2012 Sep;91(5):274-86 PubMed

J Clin Endocrinol Metab. 2013 May;98(5):E914-22 PubMed

J Clin Endocrinol Metab. 2008 May;93(5):1600-8 PubMed

J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7 PubMed

Cancer Res. 2008 Jun 1;68(11):4183-91 PubMed

Cancer Cytopathol. 2016 Sep;124(9):616-20 PubMed

Head Neck. 2010 Jan;32(1):38-45 PubMed

Adv Anat Pathol. 2001 Nov;8(6):345-54 PubMed

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...